title: Nutrition intervention to decrease symptoms in patients with advanced heart failure.
abstract: For a majority of patients with advanced heart failure, there is a need for complementary, non-pharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this double blind-placebo controlled study are (1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health-related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; (2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and (3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 175 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group.
authors: College of Nursing, University of Kentucky, 751 Rose Street, Lexington, KY 40536-0232, USA.
authors: Terry A
authors: TA
authors: Lennie
authors: Debra K
authors: DK
authors: Moser
authors: Martha J
authors: MJ
authors: Biddle
authors: Darlene
authors: D
authors: Welsh
authors: Geza G
authors: GG
authors: Bruckner
authors: D Travis
authors: DT
authors: Thomas
authors: Mary Kay
authors: MK
authors: Rayens
authors: Alison L
authors: AL
authors: Bailey
mesh_terms: D015415:Biomarkers / Q000097:blood; D002338:Carotenoids / Q000097:blood / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D019587:Dietary Supplements; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000178:diet therapy*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007249:Inflammation / Q000178:diet therapy; D000077276:Lycopene; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress; D010166:Palliative Care; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood
chemical_list: D015415:Biomarkers; D015525:Fatty Acids, Omega-3; D014527:Uric Acid; C075750:8-epi-prostaglandin F2alpha; D002338:Carotenoids; D008315:Malondialdehyde; D015237:Dinoprost; D000077276:Lycopene